| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS)
PHAS Technical Analysis
5
| As on 4th Jan 2023 PHAS STOCK Price closed @ 0.04 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.27 & Strong Sell for SHORT-TERM with Stoploss of 3.29 we also expect STOCK to react on Following IMPORTANT LEVELS. |
PHASSTOCK Price
| Open | 0.04 | Change | Price | % |
| High | 0.04 | 1 Day | 0.00 | 0.00 |
| Low | 0.03 | 1 Week | 0.02 | 100.00 |
| Close | 0.04 | 1 Month | -0.08 | -66.67 |
| Volume | 285749 | 1 Year | -3.50 | -98.87 |
| 52 Week High 4.05 | 52 Week Low 0.02 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| PHAS Daily Charts |
PHAS Intraday Charts |
Whats New @ Bazaartrend |
PHAS Free Analysis |
|
|
PHAS Important Levels Intraday
| RESISTANCE | 0.06 |
| RESISTANCE | 0.05 |
| RESISTANCE | 0.05 |
| RESISTANCE | 0.05 |
| SUPPORT | 0.03 |
| SUPPORT | 0.03 |
| SUPPORT | 0.03 |
| SUPPORT | 0.02 |
PHAS Forecast April 2024
| 4th UP Forecast | 2.12 |
| 3rd UP Forecast | 1.45 |
| 2nd UP Forecast | 1.04 |
| 1st UP Forecast | 0.63 |
| 1st DOWN Forecast | -0.55 |
| 2nd DOWN Forecast | -0.96 |
| 3rd DOWN Forecast | -1.37 |
| 4th DOWN Forecast | -2.04 |
PHAS Weekly Forecast
| 4th UP Forecast | 0.89 |
| 3rd UP Forecast | 0.62 |
| 2nd UP Forecast | 0.45 |
| 1st UP Forecast | 0.28 |
| 1st DOWN Forecast | -0.20 |
| 2nd DOWN Forecast | -0.37 |
| 3rd DOWN Forecast | -0.54 |
| 4th DOWN Forecast | -0.81 |
PHAS Forecast2024
| 4th UP Forecast | 7.92 |
| 3rd UP Forecast | 5.39 |
| 2nd UP Forecast | 3.83 |
| 1st UP Forecast | 2.27 |
| 1st DOWN Forecast | -2.19 |
| 2nd DOWN Forecast | -3.75 |
| 3rd DOWN Forecast | -5.31 |
| 4th DOWN Forecast | -7.84 |
PhaseBio Pharmaceuticals Inc ( NASDAQ USA Symbol : PHAS )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
PHAS Business Profile
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. Address: 1 Great Valley Parkway, Malvern, PA, United States, 19355
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service